Fizer Vet-Loss ends development of Danuglipron
Physicians have stopped the development of danuglipron pellets after a test patient experiences a potential drug-inspired liver injury.
In short
- Fizer said that it has stopped growing experimental weight loss pill
- A test patient experienced a potential drug-inspired liver injury
- This will continue to develop another experimental oral medicine targeting GIPR hormones
Fizer said on Monday that it has stopped the development of experimental weight-loss danuglipron after a test patient experienced a potential drug-inspired liver injury that was resolved after the drug was shut down.
The Fizzer was testing several doses of the one-day version of the oral drug candidate after the development of a twice-the-grade version at the end of 2023, as most patients excluded a midstage test due to the high rate of side effects such as nausea and vomiting.
Danuglipron is part of a square of drugs designed to target an intestinal hormone called GLP-1.
The weight loss category has drawn high interest from pharmaceutical companies and investors, with annual sales forecasts, a hit of $ 150 billion in the coming years, new, highly effective drugs have increased external demand.
The market currently dominated Novo Nordisk’s Vegovi and Elli Lily’s Zapebound, both are given as a weekly injection. Many companies are expected to declare step 3 test results for their drug orforglipron on any day, which are working on more convenient GLP-1 tablets, including Lily.
Fizer said that the dose-euphemical study of the once-danage danuglipron was received from the major pharmacocynetic purposes and in 1,400 study participants in comprise the drugs approved in the overall frequency category of liver enzyme height. A patient, however, developed a liver injury.
Fizer said that “after reviewing the totality of information, which includes recent inputs from all clinical data and regulators generated to Danuglipron till date,” decided to stop studying the molecule. Drug manufacturer’s shares fell 1.2% in premarket trading.
The company said it will continue the development of a separate hormone, GIPR and other earlier obesity programs to the development of its experimental oral drug.
Chris Bosoff, Chief Scientific Officer of Fizer, said in a statement, “Heart and metabolic diseases including obesity, which remain an important area of obesity requirement, and we are planning to implement our global abilities to carry forward a pipeline for investigation.”
Fizer said that the data of the Denglipron Clinical Program would be presented at the future scientific meeting or for publication in a magazine reviewed by a colleague.
